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Significance 
This systematic review found that pain in cancer patients is associated with abnormal sensory 
responses to thermal, mechanical and pinprick stimuli. However, these findings are based 
primarily on studies of chemotherapy-induced peripheral neuropathy and data on tumour-
related pain are lacking, warranting further research. 
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Abstract 
Objective: To summarises the literature on the use of quantitative sensory testing (QST) in the 
assessment of pain in people with cancer and to describe which QST parameters consistently 
demonstrate abnormal sensory processing in patients with cancer pain. 
Databases and Data Treatment: Medline, EMBASE, AMED, CINAHL, SCOPUS and CENTRAL were 
searched for observational or experimental studies using QST in patients with a cancer diagnosis and 
reporting pain. Search strategies were based on the terms ‘quantitative sensory testing’, ‘cancer’, 
‘pain’, ‘cancer pain’ and ‘assessment’. Databases were search from inception to January 2019. Data 
were extracted and synthesised narratively, structured around the different QST modalities and sub-
grouped by cancer pain aetiology (tumour- or treatment-related pain) 
Results: Searches identified 286 records of which 18 met the eligibility criteria for inclusion. Three 
studies included patients with tumour-related pain, and 15 studies included patients with pain from 
chemotherapy induced peripheral neuropathy (CIPN). Across all studies, 50% (9/18) reported sensory 
abnormities using thermal detection thresholds (cool and warm), 44% (8/18) reported abnormal 
mechanical detection thresholds using von-Frey filaments and 39% (7/18) found abnormal pin-prick 
thresholds. Abnormal vibration and thermal pain (heat/cold) thresholds were each reported in a third 
of included studies. 
Conclusion: This systematic review highlights the lack of published data characterising the sensory 
phenotype of tumour-related cancer pain. This has implications for our understanding of the 
underlying pathophysiological mechanisms of cancer pain. Understanding the multiple mechanisms 
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Introduction 
A third of patients receiving anticancer treatment report moderate to severe pain and over 
50% of patients with advanced cancer report moderate to severe pain. Forty percent of 
patients with cancer are affected by neuropathic pain which is associated with higher levels 
of pain and reduced quality of life (van den Beuken-van Everdingen et al. 2007, Breivik et al. 
2009, Bennett et al. 2012, Rayment et al. 2012, ONS 2015). As survival rates for cancer rise 
(Kumar 2011), the burden of living with chronic pain from cancer and its treatment is rapidly 
becoming a global health problem. Furthermore, the reduction in cancer pain prevalence 
seen in the second half of the 20
th
 century (following publication of the WHO analgesic ladder 
in cancer pain) has stalled in the past decade (van den Beuken-van Everdingen et al. 2018). 
Accurately diagnosing cancer pain based on aetiology and neurological mechanisms is 
essential to provide targeted and effective treatments for cancer patients (Mulvey et al. 
2014, Mulvey et al. 2017). 
Approximately 76% of cancer pains are caused by the tumour itself (tumour-related cancer 
pain) and is regarded as a mixed-mechanism pain (Grond et al. 1996). Tumour-related cancer 
pain is difficult to treat as nociceptive, inflammatory and neuropathic mechanisms commonly 
co-exist, particularly in bone (Grond et al. 1999, Caraceni et al. 2005, Piano et al. 2012, Pina 
et al. 2014, Paice et al. 2016)metastases (Paley et al. 2011, Falk et al. 2014). As cancer 
treatments become more sophisticated, exposure to anti-cancer therapies (such as 
chemotherapy, surgery or radiotherapy) is recognised as an important cause of pain in 
patients with cancer (Paice et al. 2016). Between 10-20% of cancer pains are caused by anti-
cancer therapies (treatment-related cancer pain) (Grond et al. 1996, Grond et al. 1999, 
Bennett et al. 2012) which are considered more similar to classic peripheral neuropathic pain 
in mechanism and character (Paice et al. 2016). The remainder of pains in cancer patients are 
due to co-morbid diseases unrelated to cancer. Identifying the most predominate pain 
mechanism(s) is essential to diagnosing cancer pain and tailoring treatment plans. 
A 2012 systematic review estimated that 40% of cancer patients with pain have a dominance 
of neuropathic mechanisms, which can be either tumour-related or treatment-related 
(Bennett et al. 2012). Neuropathic cancer pain (NCP) is associated with greater analgesic 
requirements and oncological treatments, as well as poorer quality of life and lower 
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exacerbations of pain (pain flares) that peak multiple times per day (Fallon 2013). These 
spontaneous pain flares are usually located in areas where there is observed sensory 
dysfunction (hypersensitivity and/or hyposensitivity) (Fallon 2013, Haanpaa 2013, Baron et al. 
2017). Patients with NCP also experience other sensations such as dysesthesia, allodynia and 
hyperalgesia (Fallon 2013, Haanpaa 2013, Paice et al. 2016). 
Pain assessment and diagnostic guidelines propose the use of objective measurable tests 
such as quantitative sensory testing (QST,  
 
Table 1) to support the diagnosis of neuropathic pain (Cruccu et al. 2009, Cruccu et al. 2010, 
Haanpaa et al. 2011, Piano et al. 2012, Piano et al. 2013, Finnerup et al. 2016). QST has been 
used most frequently in the assessment of peripheral neuropathic pain syndromes to defined 
thermal and mechanical stimuli (Rolke et al. 2006, Roldan et al. 2015). In cancer, QST has 
primarily focused on the assessment of peripheral neuropathy associated with exposure to 
chemotherapy (Lipton et al. 1987, Lipton et al. 1991, Augusto et al. 2008, Boyette-Davis et al. 
2011, Boyette-Davis et al. 2012, Boyette-Davis et al. 2013, Vichaya et al. 2013). These data 
show a consistent a pattern of loss in function of small and large sensory fibres associated 
with painful CIPN symptoms, characterised by increased thresholds to vibration, light touch 
(von Frey hair) and pinprick stimuli. These data demonstrate the potential for QST to link 
patient reported symptoms with underlying pathophysiological mechanisms.  
Nevertheless, the standardised QST protocol is labour intensive, requires expensive 
equipment and highly trained operators to complete the tests and interpret the data (Cruz-
Almeida et al. 2014). Shorter QST protocols that are both clinically predictive and simple to 
operate and interpret are likely to be more clinically useful (Cruz-Almeida et al. 2014). The 
first step towards developing a clinically relevant bedside QST protocol is to systematically 
review the literature to identify which QST parameters most frequently identify sensory 
abnormalities in tumour-related and treatment-related cancer. This will indicate which QST 
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Aim Objectives 
The aim of this systematic review is to describe QST parameters commonly used in the 
assessment of cancer pain (tumour-related or treatment-related pain) and identify which 
ones consistently demonstrate abnormal sensory processing in this patient population. 
Methods 
A systematic literature review was undertaken of studies which reported the use of QST in 
the assessment of cancer pain. This review was conducted in accordance with Centre for 
Reviews and Dissemination Guidelines (Centre for Reviews and Dissemination 2009) which 
include the PRISMA guidance on reporting study selection, (Moher et al. 2009) and included 
on the PROSPERO international register of systematic reviews (CRD42018090092). 
Eligibility Criteria / Types of studies to be included 
Studies were eligible for inclusion if they: 
1. were original observational or experimental studies 
2. included adults (≥ 16 years old) with a cancer diagnosis and reporting pain (tumour- 
or treatment-related pain) 
3. had reported using standardised quantitative sensory testing (QST) procedures 
4. included patients from primary, secondary or community care settings 
5. were written in English language 
6. were available in full-text version 
7. were published in a peer-reviewed journal 
The following were excluded: 
1. studies that had recruited patients with cancer and non-cancer pain aetiologies where 
the QST data were not reported separately for cancer and non-cancer patients 
2. case reports and systematic reviews 
3. studies that had only include data on acute post-surgical pain outcomes 
4. intervention studies where: 
- baseline data were only reported on pain free participants 
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Information sources and search strategy 
Electronic databases Ovid Medline EMBASE, AMED, CINAHL, SCOPUS and CENTRAL were 
searched from inception to March 2018. Searches were updated in January 2019. A search 
strategy was developed for Ovid Medline based on primary search terms for ‘quantitative 
sensory testing’, ‘cancer’, ‘pain’, ‘cancer pain’ and ‘assessment’ (Table 2). Additional search 
terms which encompassed the main attributes of psychophysiology and pain classification 
were also included in the searchers. Search terms were tailored to each subsequent 
database, as required. Full search strategy is described in Table 2. 
Study selection process 
Three reviewers (ASR, MRM, MEM) independently applied the eligibility criteria to the search 
results by examining the titles and abstracts. Full texts were retrieved for articles that met 
the inclusion criteria or could not be excluded based on abstract or title. Full text of relevant 
articles were assessed for inclusion independently by two authors with reasons for exclusion 
documented. Disagreement on included studies was discussed with an independent reviewer 
(MB) and consensus was reached.  
Data collection and synthesis 
Data was extracted on: study characteristics (publication year, aim, design and country); 
participants (number, age, gender, cancer diagnosis, pain aetiology, control subjects); setting 
(e.g. primary care, secondary care, research institution); outcome measures (QST, patient 
reported outcome measures (PROMS)); results (QST, PROMS); authors conclusion. Where 
data were not available, attempts were made to contact the authors for the missing 
information. 
It was intended that the data would be synthesised narratively. This synthesis was structured 
around the different QST modalities and (if sufficient data were available) cancer pain 
aetiology (i.e. tumour or treatment related pain). Where the data were available, the 
proportion of studies that included participants with advanced cancer, as well as the 
numbers and proportions of participants in each study who had advanced cancer was 
calculated. Demographic and clinical variables (including cancer types) were also summarised 
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Quality of included studies 
Methodological and reporting quality of each included study was assessed using a modified 
version the National Heart, Lung and Blood institute Study Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Studies (U.S. Department of Health & Human 
Services 2019,). The criteria assessed the quality of reporting of evidence upon which the 
conclusions of this systematic review are drawn.  
A. Research question or objective clearly stated? 
B. Study population clearly defined?  
C. Subjects selected or recruited from the same or similar populations? 
D. QST parameters clearly defined and implemented consistently across all study 
participants? 
E. Mechanism based justification for the use of individual QST parameter(s) based 
on underlying pathophysiological pain mechanisms? 




Our searches identified 189 potentially relevant studies, of which 41 full text reports were 
examined (Figure 1). A total of 18 studies met the eligibility criteria (Figure 1) (Lipton et al. 
1991, Forsyth et al. 1997, Dougherty et al. 2004, Binder et al. 2007, Cata et al. 2007, 
Dougherty et al. 2007, Caraceni et al. 2008, Attal et al. 2009, Boyette-Davis et al. 2011, 
Hershman et al. 2011, Scott et al. 2012, Boyette-Davis et al. 2013, Krøigård et al. 2014, Fallon 
et al. 2015, Velasco et al. 2015, Andersen et al. 2016, Andriamamonjy et al. 2017, Ventzel et 
al. 2017). Three studies included patients with tumour-related cancer pain (Lipton et al. 1991, 
Scott et al. 2012, Andersen et al. 2016). Fifteen studies included patients with chemotherapy 
induced peripheral neuropathy (CIPN) (Forsyth et al. 1997, Dougherty et al. 2004, Binder et 
al. 2007, Cata et al. 2007, Dougherty et al. 2007, Caraceni et al. 2008, Attal et al. 2009, 
Boyette-Davis et al. 2011, Hershman et al. 2011, Boyette-Davis et al. 2013, Krøigård et al. 
2014, Fallon et al. 2015, Velasco et al. 2015, Andriamamonjy et al. 2017, Ventzel et al. 2017). 
Across all included studies 789 participants were included: 510 had cancer pain, 73 had non-
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Study characteristics  
Eight studies were conducted in the USA and ten in Europe. Sixteen studies were 
observational: eight cross-sectional (Lipton et al. 1991, Dougherty et al. 2004, Binder et al. 
2007, Cata et al. 2007, Dougherty et al. 2007, Krøigård et al. 2014, Andriamamonjy et al. 
2017, Ventzel et al. 2017), seven prospective (Forsyth et al. 1997, Caraceni et al. 2008, Attal 
et al. 2009, Boyette-Davis et al. 2011, Boyette-Davis et al. 2013, Velasco et al. 2015, Andersen 
et al. 2016), and one used cross-sectional and prospective groups (Hershman et al. 2011). 
Two studies were experimental trials of analgesic interventions; only baseline (pre 
intervention) QST data were extracted (Scott et al. 2012, Fallon et al. 2015). Three studies 
also included cancer patients without pain (Binder et al. 2007, Krøigård et al. 2014, Andersen 
et al. 2016). For each study, only QST data on patients who reported pain were extracted. 
The most common cancers were colorectal and breast (Table 3).  
Of the 15 CIPN studies, five included patients with acute pain symptoms (Forsyth et al. 1997, 
Binder et al. 2007, Caraceni et al. 2008, Velasco et al. 2015, Andriamamonjy et al. 2017) and 
10 included patients with chronic pain symptoms (Dougherty et al. 2004, Cata et al. 2007, 
Dougherty et al. 2007, Attal et al. 2009, Boyette-Davis et al. 2011, Hershman et al. 2011, 
Boyette-Davis et al. 2013, Krøigård et al. 2014, Fallon et al. 2015, Ventzel et al. 2017) 
following chemotherapy administration. Data from the three tumour-related pain studies 
could not be categorised as acute/chronic due to the ongoing nature of advancing disease 
over an extended period of time. The three studies reporting data on tumour-related pain all 
included patients with chronic pain (i.e. pain longer than 3 months). Across all studies, the 
mean (SD, range) age was 58 (6.6, 48-73) and 63% of cancer pain participants were female. 
Age and gender of non-pain participants were not extracted.  
Quality assessment of included studies 
A summary of the quality of included studies is reported in Table 4. All studies reported a 
clearly stated research question and/or the objectives [A], except Lipton et al (Lipton et al. 
1991) for whom the research objectives were not explicitly stated. The study populations 
were clearly described in all studies [B] and recruited from the same or similar populations 
[C]. All studies described the QST parameters that were employed, or indicated that the DNFS 
QST protocol (Rolke et al. 2006) was adhered to [D]. In addition, all studies clearly defined the 
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Studies varied in terms of the extent to which the choice of QST parameters was justified by a 
priori theory of underlying pain mechanisms [E]. Few studies made direct links between pain 
symptoms, the underlying neurobiological mechanism, and the selection of the appropriate 
QST parameter. Four studies presented no justification for the selection of QST parameters 
they used (Forsyth et al. 1997, Cata et al. 2007, Caraceni et al. 2008, Krøigård et al. 2014). Six 
studies cited previous literature on sensory symptoms associated with tumour-related or 
treatment-related cancer pain (Dougherty et al. 2007, Boyette-Davis et al. 2011, Hershman et 
al. 2011, Boyette-Davis et al. 2013, Fallon et al. 2015, Andersen et al. 2016). Three studies 
justified QST selection by linking individual symptoms to QST parameters and associated 
underlying pathophysiological mechanisms. Andriamamonjy et al (Andriamamonjy et al. 
2017)
 
linked previously reported transient cold-induced distal allodynia with the assessment 
of thermal detection and thermal pain thresholds in oxaliplatin induced neuropathy Attal et 
al (Attal et al. 2009) justified the selection of QST parameters based on their ability to detect 
sensory loss, hyperalgesia or allodynia which were previously reported to be associated with 
oxaliplatin therapy. Dougherty et al (Dougherty et al. 2004) linked individual CIPN symptoms 
to QST parameters and underlying pathophysiological mechanisms: sensory data on 
mechanical, heat and cold perception pain to assess function in specific fibre types within 
areas of sensory disturbance in patients with painful CIPN. In two studies sensory 
abnormalities of CIPN were profiled using all 13 QST parameters described in the DFNS 
protocol. The authors of these studies stated their intention was to characterise large and 
small fibre function in CIPN patients and relate sensory profiles to underlying 
pathophysiological mechanisms (Binder et al. 2007, Ventzel et al. 2017). 
Thermal detection thresholds (CDT/WDT) 
Cold (CDT) and warm (WDT) detection thresholds were the most commonly assessed QST 
parameters in fifteen studies of which nine (60%) identified abnormal thermal detection 
thresholds. Lipton et al (Lipton et al. 1991) found elevated thermal detection thresholds in 
the feet of 50% of a heterogeneous cohort of 29 patients with tumour-related pain (Table 5). 
Scott et al. observed a variety of hypo- and hyper-sensitivity to warm and cool stimuli (Scott 
et al. 2012). Anderson et al. did not observe altered cool or warm perception (Andersen et al. 
2016). Of the 12 CIPN studies that evaluated thermal detection thresholds, four reported 
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Ventzel et al. 2017), two reported elevated CDT (Forsyth et al. 1997, Dougherty et al. 2004), 
and one reported that both CDT and WDT were elevated (Cata et al. 2007).  
Thermal pain thresholds (CPT/HPT) 
Cold (CPT) and heat (HPT) pain thresholds were reported in twelve studies of which six (50%) 
reported abnormal thermal pain thresholds. Only Andersen et al. (Andersen et al. 2016) 
evaluated thermal pain thresholds in tumour-related pain, but found no difference. Six of 11 
CIPN studies that evaluated HPT and/or CPT identified abnormal thermal pain processing 
(Table 5). Four studies observed a reduction in CPT (cold-hyperalgesia) in response to 
Oxaliplatin (Binder et al. 2007, Attal et al. 2009, Velasco et al. 2015) and Bortezomib (Cata et 
al. 2007).
 
Three studies found elevated HPT (heat hypoalgesia) associated with exposure to 
Bortezomib, Paclitaxel and Vincristine (Cata et al. 2007, Boyette-Davis et al. 2011, Boyette-
Davis et al. 2013). Attal et al. observed reduced HPT (heat hyperalgesia) in response to 
Oxaliplatin (Attal et al. 2009).
 
Velasco et al. and Attal et al. also observed increased pain 
response induced by supra-threshold cold stimuli (cold hyperalgesia) (Attal et al. 2009, 
Velasco et al. 2015).
 
Paradoxical heat sensations (PHS) 
PHS were evaluated in two studies (Binder et al. 2007, Ventzel et al. 2017)
 
one of which, 
Ventzel et al., found 65% of colorectal cancer patients exposed to Oxaliplatin and 44% of 
breast cancer patients exposed to Docetaxel experienced PHS mediated by elevated WDT. 
Mechanical detection threshold (MDT) 
MDT were reported in thirteen studies of which eight (62%) detected sensory abnormalities. 
Two of three tumour-pain studies evaluated MDT (Table 5) (Scott et al. 2012, Andersen et al. 
2016). Neither observed differences in MDT when comparing a painful region with a control 
region in patients with tumour-related pain. Eleven CIPN studies assessed MDT at the site of 
pain (finger tips or toes), of which eight (72%) found elevated MDT (Table 5). One study 
found that reduced Aβ-fibre function preceded and predicted dysfunction in Aδ-fibres and C-
fibres (Dougherty et al. 2007). Three CIPN studies did not observed altered MDT (Binder et al. 
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Mechanical pain threshold (MPT) 
MPT were reported in twelve studies of which seven (58%) identified altered pinprick 
sensitivity. Two studies evaluated MPT in patients with tumour-related pain (Table 5) (Scott 
et al. 2012, Andersen et al. 2016). Neither observed differences in MPT. Of the ten CIPN 
studies that assessed MPT, seven (70%) reported altered pinprick sensations. Four studies 
found elevated MPT (pinprick hypoalgesia) (Cata et al. 2007, Dougherty et al. 2007, Boyette-
Davis et al. 2011, Boyette-Davis et al. 2013). In contrast, three studies reported reduced MPT 
(pinprick hyperalgesia) (Dougherty et al. 2004, Binder et al. 2007, Fallon et al. 2015). 
Mechanical pain sensitivity (MPS) 
Four studies evaluated MPS of which one (25%) found alerted pain response to supra-
threshold pinprick pain (Binder et al. 2007, Scott et al. 2012, Fallon et al. 2015, Ventzel et al. 
2017). Scott et al. observed pinprick hyper- and hypoalgesia (45% and 9% respectively), 
indicating mixed pathophysiology in cancer induced bone pain (CIBP) patients (Table 5) (Scott 
et al. 2012). Fallon et al., Binder et al., and Ventzel et al. all observed no difference in MPS 
(Table 5) (Binder et al. 2007, Fallon et al. 2015, Ventzel et al. 2017). 
Dynamic mechanical allodynia (DMA) 
DMA was assessed in four studies using light tactile stimuli e.g. soft burst of which one (25%) 
identified altered light touch perception. Scott et al. observed DMA in 13% of CIBP patients 
centrally augmented pain sensitisation present in a sub-set of CIBP patient (Table 5) (Scott et 
al. 2012). The authors also observed tactile hypoaesthesia in response to dynamic soft brush 
stimulus in 22% of CIPB patients. The other three studies that evaluated DMA found no 
altered sensations (Table 5) (Binder et al. 2007, Attal et al. 2009, Ventzel et al. 2017).
 
Temporal pain summation (Wind-up ratio (WUR)) 
Augmented temporal pain summation was assessed using the pinprick wind-up ratio (WUR) 
in three studies (Binder et al. 2007, Fallon et al. 2015, Ventzel et al. 2017). None (0%) of 
these CIPN studies observed increased WUR in painful regions in comparison to normative 
data sets (Binder et al. 2007), contralateral pain free region (Fallon et al. 2015) or between 
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Vibration detection threshold (VDT) 
VDT were evaluated in seven studies of which six (86%) identified altered vibration 
perception. Lipton et al. identified elevated VDT in the feet of tumour-related pain patients 
(Table 5) (Lipton et al. 1991). Of the six CIPN studies that evaluated vibration perception, five 
observed elevated VDT (Table 5) (Forsyth et al. 1997, Caraceni et al. 2008, Attal et al. 2009, 
Hershman et al. 2011, Ventzel et al. 2017). In two prospective cohorts, cumulative Paclitaxel 
(Caraceni et al. 2008) and Oxaliplatin (Attal et al. 2009) doses correlated with increasingly 
elevated VDT. However, in another prospective cohort, Hershaman et al. observed elevated 
VDT within a month of first Paclitaxel cycle which returned to baselined (pre-treatment) 
levels by 12 months (Hershman et al. 2011). In a cross-sectional cohort, Ventzel et al. found 
significantly elevated VDT in the hands (but not feet) of colorectal and breast cancer patients 
exposed to Oxaliplatin or Docetaxel respectively (Ventzel et al. 2017). In another cross-
sectional cohort, Hershman et al. identified significant negative correlation between 
increased sensations of numbness and pain in hands and feet and reduced vibration 
perception (Hershman et al. 2011).
 
 
Pressure pain threshold (PPT) 
Pressure pain thresholds (PPT) were assessed in two studies (Binder et al. 2007, Ventzel et al. 
2017). Binder et al. found no difference in PPT between those with painful CIPN and pain free 
patients (Binder et al. 2007). Ventzel et al. found PPT within normative data range for both 
Oxaliplatin and Docetaxel treated patients (Ventzel et al. 2017).
 
Variation in QST procedures 
Studies varied in terms of the different procedures used to evaluate the same or similar QST 
parameters. Lipton et al. (Lipton et al. 1991) and Forsyth et al. (Forsyth et al. 1997) reported 
measuring ‘thermal detection threshold’ (TDT) via a forced choice paradigm which most 
closely mimics evaluating CDT in terms of thermal range used (i.e. 20-30
o
C). Scott et al. (Scott 
et al. 2012) qualitatively determined presence or absence of thermal hyperaesthesia, 





C). In contrast, 12 studies quantitatively evaluated thermal detection and pain 
thresholds using computer controlled devices via a Peltier thermode (Dougherty et al. 2004, 
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al. 2011, Boyette-Davis et al. 2013, Krøigård et al. 2014, Velasco et al. 2015, Andersen et al. 
2016, Andriamamonjy et al. 2017, Ventzel et al. 2017).  
Techniques to assess vibration perception also varied. Two studies evaluated VDT using a 
forced choice paradigm to distinguish between two metal rods vibrating at increasingly 
similar frequencies (Lipton et al. 1991, Forsyth et al. 1997).
 
Two studies used a standardised 
64Hz tuning fork which decreases in frequency until the vibration is no longer felt 
(disappearance threshold) (Binder et al. 2007, Ventzel et al. 2017). Three studies used 
electronic vibrameters which increase in frequency until the vibration is felt (perception 
threshold) (Caraceni et al. 2008, Attal et al. 2009, Hershman et al. 2011). Studies that 
evaluated MDT all used von Frey monofilaments in a method of limits paradigm. However, 
punctate sensitivity was evaluated quantitatively using calibrated weighted needle pinprick 
stimulators (Binder et al. 2007, Ventzel et al. 2017) or qualitatively single pinprick stimulus 
(Neurotips
TM
 Owen Mumford) (Scott et al. 2012, Fallon et al. 2015). 
All of the four studies that included MPS in their methodology used noxious pin prick stimuli, 
two of which (Scott et al. 2012, Fallon et al. 2015) specified the Neurotips
TM 
Owen Mumford, 
whilst the remaining two studies (Binder et al. 2007, Ventzel et al. 2017) documented that 
they followed the QST-protocol of the German Research Network on Neuropathic Pain 
(DNFS).  Similarly, the three studies who included WUR in their methodology all used pin 
prick stimuli (256mN) and compared a single stimulus to ten repeated stimuli with the 
participant giving a pain rating from 0-10.  
Techniques to measure dynamic allodynia varied slightly. Of the four studies that included an 
assessment of dynamic allodynia, two studies (Binder et al. 2007, Ventzel et al. 2017) 
followed the DNFS protocol which describes using three light tactile stimulators: a cotton 
wisp (~3mN), a cotton wool tip fixed to an elastic strip (~100mN) and a standardised brush 
(~200-400mN). The remaining two studies just used a standardised brush (Attal et al. 2009, 
Scott et al. 2012). 
Finally, for the two studies that measured PPT (Binder et al. 2007, Ventzel et al. 2017), both 
studies followed the DNFS QST-protocol which uses a pressure gauge device (FDN200, 
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Discussion 
Across all studies, 50% (9/18) reported sensory abnormities using thermal detection 
thresholds (cold and warm), 44% (8/18) reported abnormal mechanical detection thresholds 
using von-Frey filaments and 39% (7/18) found abnormal pin-prick thresholds. Abnormal 
vibration and thermal pain (heat/cold) thresholds were reported in a third of included studies 
respectively. 
This systematic review demonstrates a paucity of published data characterising the 
phenotype of cancer pain using quantitative pain assessment techniques. Three studies were 
identified that characterised tumour-related pain using QST, of which only two reported data 
on sensory abnormalities (Lipton et al. 1991, Scott et al. 2012). Fifteen studies were identified 
that characterised sensory abnormalities in CIPN using QST. These treatment-related pain 
studies included a heterogeneous sample of patients with chronic and acute painful CPIN. 
The in the number of QST studies profiling sensory abnormalities associated with CIPN has 
increased in the past two decades. However, overall the number of QST studies profiling 
cancer pain are small and the data should be interpreted with caution for this reason. There 
are more recent emerging studies using QST to quantify pain in cancer patients; although 
they didn’t meet the eligibility criteria for this systematic review, they are interesting for 
reference (Kaunisto et al. 2013, Sipila et al. 2017, Griffiths et al. 2018). 
Of the three tumour-related pain studies (Lipton et al. 1991, Scott et al. 2012, Andersen et al. 
2016), Liption et al. and Scott et al. reported abnormalities in thermal detection and 
mechanical or vibration detection, indicative of Aβ and Aδ fibre dysfunction. These limited 
data suggest that systemic and localised loss in Aβ-fibre function, characterised by reduced 
light touch sensation (hypoaesthesia) may be common in tumour-related cancer pain. 
Andersen et al. found no sensory abnormalities; however, this study excluded patients with 
any kind of peripheral nerve dysfunction and therefore were very unlikely to come across any 
sensory abnormalities using QST.  
The data presented in Table 5 indicate that CIPN is predominately characterised by increased 
vibration and mechanical detection thresholds (reduced Aβ function), as well as increased 
thermal detection and thermal pain thresholds (reduced Aδ and C-fibre function). Altered 
pin-prick (mechanical pain) thresholds were also observed; however, whether this 
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dependent. Across all treatment-related studies, none identified altered perception of supra-
thresholds stimuli, such as mechanical pain sensitivity, dynamic mechanical allodynia, 
pressure pain threshold or temporal summation (wind-up pain). However, the inclusion of 
chronic and acute pain patients across the CIPN studies should also be considered. Patients 
with chronic pain typically experience higher levels of pain intensity, reduced wellbeing and 
poorer quality of life (Smith et al. 2007, Rayment et al. 2012). Chronic pain is also thought to 
be associated with more central pathophysiological pain processes (Loeser 2019) which, in 
the context of this systematic review, may influence QST findings based on peripheral 
cutaneous examination techniques. None of the included CIPN studies explicitly stated using 
QST to examine central pain mechanisms.  
We acknowledge that a limitation of this systematic review is the lack of available data on 
which to base conclusions, particularly for tumour-related pain. Despite a comprehensive 
search strategy developed in line with international guidelines (Centre for Reviews and 
Dissemination 2009, Moher et al. 2009) and broad eligibility criteria, very few studies were 
identified. Due to the paucity of available quantitative data, it was not possible to undertake 
a pooled analysis of QST data across all studies. Instead a narrative synthesis was undertaken 
to summarise the main findings and identify commonalities in the patterns of sensory 
abnormalities reported in tumour-related and treatment-related cancer pain.  
The most commonly used QST parameters were thermal detection thresholds (CDT, WDT) 
and mechanical detection. PPT and WUP were only included in 3 and 2 studies respectively 
and revealed no sensory abnormalities. No studies reported finding DMA in tumour or 
treatment related cancer pain, although this is contrary to anecdotal clinical experience of 
bedside assessment in many patients. As DMA is a centrally mediated phenomenon, this 
might suggest that tumour related pain is caused by peripheral sensitisation rather than 
central sensitisation. However, these conclusions are speculative due to the lack of available 
data. 
The majority of CIPN studies did not make explicit statements linking the selection of 
individual QST parameters to underlying pain mechanisms or patient reported symptoms. 
Therefore, it remains unclear whether the data presented on treatment-related cancer pain 
represents sensory abnormalities common to CIPN, or if it reflects the QST parameters that 
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tactile sensitivity has been widely reported as a common side effect of chemotherapy. 
Nevertheless, future cancer pain research should consider profiling all 13 DNFS parameters 
to gain a clearer understanding of which sensory abnormalities are most relevant to the 
diagnosis and management of pain in patients with cancer. 
The increasing abundance of QST evidence from CIPN studies (of a variety of 
chemotherapeutic agents) indicates dysfunction in myelinated and unmyelinated cutaneous 
sensory fibres. Similar quantitative sensory data in patients with tumour-related pain are 
lacking; although evidence presented here suggests dysfunction in both myelinated and 
unmyelinated cutaneous sensory fibres. Further research is required to map the sensory 
phenotypes of tumour-related pain to improve our understanding of the underlying 
pathophysiological mechanisms. Studies should include a heterogeneous population of 
cancer types to better understand whether patterns of sensory dysfunction are disease 
specific or unique to individual pain profiles which span cancer diagnostic groups.  
Interestingly, none of the included studies evaluated descending pain control mechanisms. 
Increasing evidence is emerging to support the theory that descending inhibitory (anti-
nociceptive) and facilitatory (pro-nociceptive) pathways are fundamental to our 
understanding of chronic and neuropathic pain as seen in cancer patients. Data from animal 
models of neuropathic pain reveals a multitude of descending pain control mechanisms 
associated with hypersensitivity to noxious and non-noxious stimuli, as well as spontaneous 
pain and central sensitization (Wang et al. 2013).
 
These data demonstrate the complexities 
associated with understanding the interactions between descending inhibitory pathways and 
the clinical presentation of pain in patients with cancer (De Felice et al. 2011). QST may be a 
potential biomarker for describing the function of these descending pain modulatory 
pathways. For example, the conditioned pain modulation (CPM) paradigm has demonstrated 
that reduced efficiency of descending control of pain is associated with the development of 
chronic pain states in cancer and non-cancer populations (Yarnitsky et al. 2014, Yarnitsky 
2015). Quantifying the function of descending pain modulatory pathways using QST would 
further our understanding of the role that such neurobiological mechanisms have on the 
clinical presentation of pain in cancer patients.  
In conclusion, this systematic review highlights the lack of published studies characterising 
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related chronic or neuropathic pain. This limits our understanding of the underlying 
pathophysiological mechanisms of cancer pain. Understanding the multiple mechanisms 
driving cancer pain will enable rational individualised analgesic treatment choices (Vardeh et 
al. 2016). Future studies should justify the selection of individual test parameters from 
standardised QST protocols (Rolke et al. 2006) and consider incorporating CPM into their 
protocols to evaluate the important role of descending pain mechanisms in cancer pain. 
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Legends for figures and tables 
Figure 1 - PRISMA flow diagram of searches, screening, eligibility and inclusion 
Figure 1 legend 
* hand searching reference lists of included studies 
 
 
Table 1 – QST modalities and associated peripheral nerve fibres tested 
Table 1 legend: 
Summary of Quantitative Sensory Testing (QST) modalities, associated bedside equivalent 
examinations and peripheral nerve fibres tested 
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Table 3 – Description of included studies 
 
Table 3 legend: 
 
† Gender of cancer pain participants only (gender of control participants not reported) 
∆ decision made that this is tumour-related PN because patients with neurotoxic chemo-
therapeutic agents and other neurotoxic medications were excluded 
∂ data are mean (SD) 
§ data are median (range) 
‡ 8 (15%) reported moderate-severe pre-treatment tumour pain. Therefore, only baseline 
data (pre-intervention) extracted 
- unable to extract age data for only pain patients 
≠ data are mean (range) 
∑ 9/16 participants had pain 
¶ control subjects consisted of 20 health pain-free volunteers and 5 pain-free chemotherapy 
naïve multiple myeloma ɸ data are mean (SD, min-max) 
* Cross-sectional group / Prospectively cohort 
± data presented for Docetaxel group of whom 80% reported pain. Oxaliplatin group 70% 
reported no pain; therefore, data not extracted 
∫ calculated by hand 
ɤ data are presented for Oxaliplatin and Docetaxel groups respectively 
ɸ data are mean (SD, min-max) 
PN = Peripheral Neuropathy 
CIPN = Chemotherapy Induced Peripheral Neuropathy 
 
 
Table 4 – Assessment of Quality 
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+ high reporting quality, ⎯  low reporting quality, ? Unable to judge 
 
Assessment criteria 
A. Research question or objective clearly stated? 
B. Study population clearly defined?  
C. Subjects selected or recruited from the same or similar populations? 
D. QST parameters clearly defined and implemented consistently across all study 
participants? 
E. Mechanism based justification for the use of individual QST parameter(s) based on 
underlying pathophysiological pain mechanisms? 













Table 5 – Quantitative Sensory Testing (QST) parameters used in cancer pain assessment 
 
Table 5 legend
* Control participants referred to in 
methods but not data are reported on them 
in results.  
† Mean data are summarised unless stated 
otherwise   
VT = Vibration Threshold 
TDT = Thermal Detection Threshold 
CDT = Cold Detection Threshold  
WDT = Warm Detection Threshold  
TSL =  Thermal Sensory Limen 
PHS = Paradoxical Heat Sensation  
CPT = Cold Pain Threshold 
HPT = Heat Pain Threshold 
MDT = Mechanical Detection Threshold  
MPT =  Mechanical Pain Threshold  
MPS = Mechanical Pain Sensitivity  
DMA = Dynamic Mechanical Allodynia  
WUR = Wind Up Ratio  
VDT = Vibration Detection Threshold 
PPT = Pressure Pain Threshold 
SCS = Suprathreshold Cold Stimulus 
ICS = Intense Cold Stimulus 
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Table 1 – QST modalities and associated peripheral nerve fibres tested 
Table 1 legend: Summary of Quantitative Sensory Testing (QST) modalities, associated bedside equivalent examinations and peripheral nerve 
fibres tested 
Type of Stimulus Nerve Fibre Tested QST Method Bedside Examination 
Mechanical Detection Threshold Aβ Von Frey Filaments Brush, cotton swab 
Dynamic Mechanical Allodynia Aβ Brush, cotton wisp, wool tip Brush, cotton swab 
Vibration Aβ Calibrated Tuning Fork Tuning fork 
Cold Detection Threshold Aδ 
Computer controlled 
thermal testing device 
Cold/ warm/ hot thermo rollers/ 
test tubes 
Warm Detection Threshold C 
Cold Pain Threshold Aδ, C 
Heat Pain Threshold Aδ, C 
Mechanical Pain Threshold Aδ 
Needle Stimulators (pin 
prick) 
Toothpick, pin 
Mechanical Pain Sensitivity Aδ Toothpick, pin 
Wind-up (Temporal Summation) Aδ Toothpick, pin 
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Table 2 – Search Strategy 
Quantitative sensory testing  Pain 
 
 Cancer  Assessment 
















QST pain malignancy identif* 
psychophysical somatosensory radiotherapy categor* 
psycho-physical somato-sensory chemotherapy phenotype 
cold threshold sens* metastatic profile 
warm threshold  bone pain outcome 
pain threshold  tumour management 
detection threshold  neoplasm  
  thoracotomy  
  mastectomy  
Combined with OR Combined with OR Combined with OR Combined with OR 
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Table 3 – Description of included studies 








M†      F† 
Age 
Mean (range) 
Tumour-related pain          









129 29 100 14 15 56.8
∂
 




Tumour: CIBP 23 23 0 13 10 73 (33–83)§ 
Anderson (2016) Denmark Breast Tumour: Breast 54 8
‡
 0 0 8 - 
Treatment-related pain - CIPN        











This article is protected by copyright. All rights reserved 




Treatment: Paclitaxel 29 12 17 4 8 53.8 (18)
∂
 
Binder (2007) Germany Colon, Oesophagus, 
Gastric. 
Treatment: Oxaliplatin 16 9
∑
 0 4 5 64.6 (12.4)
∂
 
Cata (2007) USA Myeloma, 
Lymphoma. 
Treatment: Bortezomib 41 16 25
¶
 12 4 61.7 (8)
∂
 
Doughty (2007) USA Haematological, 
Ewing’s sarcoma, 
Breast. 
Treatment: Vincristine 18 18 0 10 8 49.3 (12.1)
∂
 
Caraceni (2008) Italy Breast (metastatic) Treatment:  Paclitaxel 44 44 0 0 44 48.5 (33–64 )≠ 





Treatment: Oxaliplatin 48 48 0 33 15 58.9 (11.5)
∂
 
Boyette-Davis (2011) USA Myeloma Treatment: Bortezomib 37 11 26 7 4 58.2 (3.4)
∂
 















Boyette-Davis (2013) USA Lung, Breast, 
Haematological, 
Ewing's Sarcoma. 
Treatment: Paclitaxel & Vincristine 32 14 18 5 9 60.1 (2.3)
∂
 
Kroigard (2014) Denmark Colorectal, Breast. Treatment: Docetaxel 40 20
±
 0 14 6 53.1 (8)
∫
 
Fallon (2015) UK Colorectal, 
Myeloma, Lung, 
Ovary, Breast. 
Treatment: Oxaliplatin, Paclitaxel, 
Taxotere, Bortezomib, Cisplatin, 
Carboplatin 
51 51 0 19 32 61 (20 -89)
§
 
Velasco (2015) Spain Colorectal (stag not 
reported). 







Treatment: Oxaliplatin 12 12 0 7 5 64.5 (11.7)
∂
 










    Totals 789 510 181 161 320 58 (6.6, 48-73)
ɸ
 
Table 3 legend: 
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∆ decision made that this is tumour-related PN because patients with neurotoxic chemo-therapeutic agents and other neurotoxic medications 
were excluded 
∂ data are mean (SD) 
§ data are median (range) 
‡ 8 (15%) reported moderate-severe pre-treatment tumour pain. Therefore, only baseline data (pre-intervention) extracted 
- unable to extract age data for only pain patients 
≠ data are mean (range) 
∑ 9/16 participants had pain 
¶ control subjects consisted of 20 health pain-free volunteers and 5 pain-free chemotherapy naïve multiple myeloma ɸ data are mean (SD, min-
max) 
* Cross-sectional group / Prospectively cohort 
± data presented for Docetaxel group of whom 80% reported pain. Oxaliplatin group 70% reported no pain; therefore, data not extracted 
∫ calculated by hand 
ɤ data are presented for Oxaliplatin and Docetaxel groups respectively 
ɸ data are mean (SD, min-max) 
PN = Peripheral Neuropathy 
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Table 4 – Assessment of Quality 
Author, year A B C D E F 
Andersen et al, 2016 + + + + + + 
Andriamamonjy et al, 2016 + + + + + + 
Attal et al, 2009 + + + + + + 
Binder et al, 2007 + + + + + + 
Boyette-Davis et al, 2013 + + + + + + 
Boyette-Davis et al, 2011 + + + + + + 
Caraceni et al, 2008 + + + + ⎯ + 
Cata et al, 2007 + + + + ⎯ + 
Dougherty et al, 2007 + + + + + + 
Dougherty et al, 2004 + + + + + + 
Fallon et al, 2015 + + + + + + 
Forsyth et al, 1997 + + + + ⎯ + 
Hershman et al, 2011  + + + + + + 
Kroigard et al, 2014 + + + + ⎯ + 
Lipton et al, 1991 ? + + + + + 
Scott et al, 2012 + + + + + + 
Velasco et al, 2015 + + + + + + 
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Table 4 legend: 
+ high reporting quality, ⎯  low reporting quality, ? Unable to judge 
Assessment criteria 
A. Research question or objective clearly stated? 
B. Study population clearly defined?  
C. Subjects selected or recruited from the same or similar populations? 
D. QST parameters clearly defined and implemented consistently across all study participants? 
E. Mechanism based justification for the use of individual QST parameter(s) based on underlying pathophysiological pain mechanisms? 










Table 5 – Quantitative Sensory Testing (QST) parameters used in cancer pain assessment 
Author (Year) QST reported in 
Methods 
Test site Control site / Comparison 
group 
Abnormal QST† (clinical sign) 
Tumour-related pain 
Lipton (1991) VT, TDT Hands and feet Comparison between hand 
and feet 
37% of cases had elevated VT (mechanical 
hypoaesthesia) in feet. 50% of cases had elevated TDT 
(thermal hypoaesthesia) in feet. No sensory dysfunction 
in hands.  
Scott (2012) DMA, MDT,  
MPT, MPS,  
WDT (40oC), 
CDT (25oC) 
Skin overlying area of 
CIBP 
Contralateral or proximal non-
painful site 
Brush allodynia 13%, brush hypoaesthesia in 22%, 
pinprick hyperalgesia in 45%, pinprick hypoalgesia in 9%, 
warm allodynia in 43%, cold allodynia in 35%, thermal 




WDT, CDT, HPT, 
Pathological side Contralateral or proximal non-
painful site 
None 
Treatment-related pain - Chemotherapy Induced Peripheral Neuropathy (CIPN) 
Forsyth (1997) VT, TDT Hands and feet Control participants* VT 'abnormal' (hypo/hyper-aesthesia) in foot in 74% of 
cases in feet. TDT elevated (thermal hypoaesthesia) in 
43% of cases in feet and 12% of cases in hands.  
Dougherty 
(2004) USA 
MDT, MPT,  
CDT, CPT,  
WDT, HPT 
Pain area (tip of index 
finger), broader area 
(thenar eminence), 
distal non-painful area 
(forearm) 
Control participants MDT elevated (mechanical hypoaesthesia) in all areas. 
MPT reduced in pain and boarder areas. CDT reduced 
(cold allodynia). No difference in WDT, HPT or CPT. 
Binder (2007) CDT, WDT, 
TSL, PHS,  
CPT, HPT,  
MDT, MPT, 
MPS, 
Dorsum right hand Normative data set  
(data not reported) 
CPT reduced (cold allodynia), MPT reduced (mechanical 
hyperalgesia) 
Author (Year) QST reported in 
Methods 
Test site Control site / Comparison 
group 
Abnormal QST† (clinical sign) 




MDT, MPT,  
CDT, CPT,  
WDT, HPT 
Pain area (tip of index 
finger), boarder area 
(thenar eminence), 
distal non-painful area 
(forearm) 
Control participants MDT elevated in all areas. MPT elevated in pain area 
only. WDT and HPT elevated in all areas. CPT reduced in 
all areas. No differences in CDT. 
Doughty 
(2007) 
MDT, MPT,  
CDT, CPT,  
WDT, HPT 
Pain area (tip of index 
finger), boarder area 
(thenar eminence) 
Distal non-painful area 
(forearm) 
MDT elevated (mechanical hypoaesthesia) at painful site 
and proximally. Elevated MPT (mechanical hypoalgesia) 
and WDT (thermal hypoaesthesia) at painful site.  
Caraceni 
(2008) 
VDT Hands and feet Comparison between hand 
and feet 
Elevated VDT (mechanical hypoaesthesia) correlated 
with cumulative paclitaxel dose. Deficits in foot greater 
than hand. 
Attal (2009) DMA, VDT, 
MDT, MPT, 
CDT, WDT,  
CPT, HPT 
Hands and feet Comparison between hand 
and feet 
VDT elevated (mechanical hypoaesthesia), CPT & HPT 
decreased (cold/heat allodynia), increased 




WDT, HPT,  
CDT, CPT 
Pain area (tip of index 
finger), boarder area 
(thenar eminence), 
distal non-painful area 
(forearm) 
Control participants MDT twice that of controls (mechanical hypoaesthesia) 
in painful and boarder area at BL and 12 months. MPT 
elevated (mechanical hypoalgesia) at fingertips only at BL 
and FU. WDT and HPT elevated (thermal hypo-
aesthesia/algesia) in all areas at BL. At FU WDT and HPT 
deficits remained in painful area  
Hershman 
(2011) 
MDT, VDT Hands and feet Correlation with NP symptom 
items; pre/post intervention 
QST data comparison 
Cross-sectional data: VDT negatively correlated with 
numbness and discomfort in hands (mechanical 
hypoesthesia). Prospective data: significantly elevated 
VDT (mechanical hypoalgesia) one-month after Paclitaxel 
normalised by 12. No change in MDT at any time point. 
Author (Year) QST reported in 
Methods 
Test site Control site / Comparison 
group 
Abnormal QST† (clinical sign) 
Boyette-Davis 
(2013) 
MDT, MPT,  
WDT, HPT,  
CDT, CPT 
Pain area (tip of index 
finger), boarder area 
(thenar eminence), 
Distal non-painful area 
(forearm) 
Control participants MDT deficits at BL and FU in painful and boarder area 
(mechanical hypoaesthesia).  Persistent MPT deficits in 
painful area (mechanical hypoalgesia). BL WDT elevated 
at all three areas (thermal hypoaesthesia). HPT elevated 
at FU at all three areas (thermal hypoalgesia). 
Kroigard 
(2014)  
CDT, WDT,  
HPT, MDT, MPT 
Not reported Not reported MDT elevated (hypoaesthesia) 
Fallon (2015) MDT, MPT,  
MPS, WUR 
Site of pain Contralateral or proximal non-
painful site 
MDT elevated (mechanical hypoaesthesia), MPT reduced 
(mechanical hyperalgesia) 
Velasco (2015) CDT, WDT,  
CPT, HPT,  
SCS , ICS 
Thenar eminence of 
hand 




CDT, WDT,  
CPT, HPT 
Thenar and fingertips Within patients comparison 
between thenar and fingertip 
CDT and WDT reduced (thermal hyperesthesia). No 
differences in CPT or HPT.  
Ventzel (2017) CDT, WDT, 
TSL, PHS, 
CPT, HPT, 
MDT, MPT,  
MPS, DMA,  
WUR, VDT, PPT 
Hands and feet Unclear MDT and VDT elevated (mechanical hypoaesthesia). PHS 




* Control participants referred to in 
methods but not data are reported on them 
in results.  
† Mean data are summarised unless stated 
otherwise   
VT = Vibration Threshold 
TDT = Thermal Detection Threshold 
CDT = Cold Detection Threshold  
WDT = Warm Detection Threshold  
TSL =  Thermal Sensory Limen 
PHS = Paradoxical Heat Sensation  
CPT = Cold Pain Threshold 
HPT = Heat Pain Threshold 
MDT = Mechanical Detection Threshold  
MPT =  Mechanical Pain Threshold  
MPS = Mechanical Pain Sensitivity  
DMA = Dynamic Mechanical Allodynia  
WUR = Wind Up Ratio  
VDT = Vibration Detection Threshold 
PPT = Pressure Pain Threshold 
SCS = Suprathreshold Cold Stimulus 
ICS = Intense Cold Stimulus 
Figure 1 - PRISMA flow diagram of searches, screening, eligibility and inclusion 
 
 
Figure 1 legend 
* hand searching reference lists of included studies 
Records identified through 
database searching 


































Additional records identified 
through other sources* 
(n = 12) 
Unique records after duplicates 
removed – titles & abstracts screened 
(n = 189) 
Records excluded 
(n = 148) 
Full text articles 
reviewed 
(n = 41) Articles excluded with reasons: 
QST data not presented 
separately for pain patients =12 
Duplicated data =1 
Healthy volunteers only =1 
Studies met eligibility 
criteria and included 
(n = 18) 
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